Next-gen molecular assay play, Biofidelity secures seed financing and appoints Dr Heiner Dreismann as Senior Advisor

• Veteran Roche executive with more than 35 years of industry experience
• Pioneer in the early adoption of polymerase chain reaction (PCR) technology
• Appointment follows completion of $12 million Series A financing

CAMBRIDGE, United Kingdom, Sept. 10, 2020 (GLOBE NEWSWIRE) — Biofidelity Ltd, the cancer diagnostics company, today announces the appointment of Dr. Heiner Dreismann, former President and CEO of Roche Molecular Systems, as Chairman with immediate effect. Biofidelity recently announced the successful completion of a $12m Series A financing led by BlueYard Capital and backed by experienced investors including Longwall Ventures and Agilent Technologies. 

Dr Barnaby Balmforth, Chief Executive Officer of Biofidelity, commented: “We are delighted to welcome Heiner to the helm of the Company as Chairman.  Heiner’s diagnostics and industry expertise will be invaluable as we seek to revolutionize access to best-in-class cancer diagnostics.  Biofidelity’s unique technology platform provides high quality, comprehensive and clinically actionable information of guideline-recommended markers in a simple, high precision, rapid diagnostic to ensure every patient has access to the right treatment at the right time.”